CLINICAL TRIALS PROFILE FOR ERBITUX

All Clinical Trials for ERBITUX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00034541 ↗	Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer	Completed	Greenwich Hospital	Phase 1/Phase 2	2000-12-01	The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease progression or until the patient exhibits intolerable toxicities. Patients will be evaluated for efficacy and safety throughout the duration of the study.
NCT00034541 ↗	Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer	Completed	Indiana University	Phase 1/Phase 2	2000-12-01	The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease progression or until the patient exhibits intolerable toxicities. Patients will be evaluated for efficacy and safety throughout the duration of the study.
NCT00034541 ↗	Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer	Completed	IUPUI, Indianapolis, IN	Phase 1/Phase 2	2000-12-01	The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease progression or until the patient exhibits intolerable toxicities. Patients will be evaluated for efficacy and safety throughout the duration of the study.
NCT00034541 ↗	Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer	Completed	University of Colorado, Denver	Phase 1/Phase 2	2000-12-01	The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease progression or until the patient exhibits intolerable toxicities. Patients will be evaluated for efficacy and safety throughout the duration of the study.
NCT00034541 ↗	Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer	Completed	Eli Lilly and Company	Phase 1/Phase 2	2000-12-01	The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease progression or until the patient exhibits intolerable toxicities. Patients will be evaluated for efficacy and safety throughout the duration of the study.

Clinical Trial Conditions for ERBITUX

Condition Name

Condition Name for ERBITUX
Intervention	Trials
Colorectal Cancer	45
Head and Neck Cancer	40
Metastatic Colorectal Cancer	29
Squamous Cell Carcinoma of the Head and Neck	14

Condition MeSH

Condition MeSH for ERBITUX
Intervention	Trials
Colorectal Neoplasms	103
Head and Neck Neoplasms	89
Carcinoma, Squamous Cell	77
Carcinoma	72

Clinical Trial Locations for ERBITUX

Trials by Country

Trials by Country for ERBITUX
Location	Trials
China	53
Italy	51
Canada	51
France	34
Japan	33

Trials by US State

Trials by US State for ERBITUX
Location	Trials
Texas	73
California	64
New York	56
Pennsylvania	56
Florida	51

Clinical Trial Progress for ERBITUX

Clinical Trial Phase

Clinical Trial Phase for ERBITUX
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	34
Phase 2/Phase 3	10

Clinical Trial Status

Clinical Trial Status for ERBITUX
Clinical Trial Phase	Trials
Completed	161
Terminated	57
Recruiting	47

Clinical Trial Sponsors for ERBITUX

Sponsor Name

Sponsor Name for ERBITUX
Sponsor	Trials
National Cancer Institute (NCI)	52
Bristol-Myers Squibb	46
Eli Lilly and Company	40

Sponsor Type

Sponsor Type for ERBITUX
Sponsor	Trials
Other	364
Industry	282
NIH	55